The Symposium takes brain health on a time-journey over the pioneering R&D and disruptive technologies that capture and improve brain-plasticity and brain-fitness over a life-time. The scope of the meeting is to foster the exchange between interdisciplinary scientists, technologists and opinion leaders.

Dr Beher will present “OGA inhibitors to target intracellular protein aggregation and neuronal dysfunction in Alzheimer’s and Parkinson’s disease” on November 30th at 5:35pm CET (11:35am EST), at the session II – Technologies of the present.

BrainFit4Life is a non-profit organization composed of world-renowned scientists, clinicians, companies, foundations and patients’ organization who specialize in neurological diseases, particularly brain aging disorders, a major public health issue in Switzerland, and worldwide.

Further information about BrainFit4Life 

On October 17-19, 2021, the American Neurological Association will host its second interactive, virtual meeting experience.

Our Head of Translational Medicine Dr Ryan Schubert will present “ASN51, an Orally Bioavailable Small-molecule O-Glcnacase Inhibitor, Has Both Immediate and Disease-modifying Benefits in Preclinical Models of Parkinson’s Disease and Epilepsy” at the poster tour session “Movement Disorders 2” on October 18, 2021 at 6:30 PM ET.

ANA2021 is considered the top meeting for academic neurologists and neuroscientists at every career stage, offering the opportunity to connect over groundbreaking research and best practices for success in the field.

The 22nd International Conference on Alzheimer’s Drug Discovery showcases the innovative approaches of Alzheimer’s Drug Discovery Foundation’s (ADDF) funded scientists and their newest results. In addition to featuring ADDF’s portfolio, the program also includes guest presentations focusing on the latest research in the Alzheimer’s disease field.

Dr Dirk beher has been invited to give a lecture on “OGA inhibitors as multimodal drugs for intracellular proteinopathies”, on October 4th at 4:45 PM CET (10:45 AM ET). This presentation is part of the session #1 “Clinical Trials and Novel Approaches for Dementia”.

The purpose for the annual ADDF conference is to accelerate the development of innovative treatments for Alzheimer’s disease, related dementias and cognitive aging. Attendees will see the diverse cutting-edge approaches ADDF scientists are undertaking and have opportunities for networking and partnership discussions with academic, industry, and foundation thought leaders.

The event will be held online October 4-5, 2021 : further information and program

Genesis Digital 2020, the 20th annual London Life Science, Healthcare and Technology networking conference, was held virtually on Thursday 10th December 2020.

Genesis Digital 2020 assembles key biotechs, R&D companies, academics, members organisations, professional services and technology transfer groups. The aim of the conference is not to predict the next 20 years of industry development, but to gain a deep understanding of the current landscape to prepare for what is to come.

Virtual sessions “Around the World” were featuring key opinion leaders from different parts of the world. Our CEO Dirk Beher had the opportunity to share his experience on discovering innovative and effective therapeutics in the virtual session “Around the World in Neurodegeneration Drug Discovery”.

The Tau2020 Global Conference will gather leading tau experts from around the world with peers from academia, industry, government and the philanthropic sector to discuss key issues impacting the tau research community. It will be held on February 12th-13th at the Mariott Marquis hotel, in Washington, D.C. 

Our CEO Dirk Beher will contribute to the panel discussion “Early Stage Investment in Tau Therapeutics” on Thursday, February 13th from 4:40 pm to 5:15 pm, at Tau2020.